Slide 1: Exchange filing cover letter for investor presentation
Laurus Labs Limited Corporate Office 2"d Fl oor, Sere ne Chambers, Road No. 7 Banjara Hi lls, Hyderabad- 50003~, Telangana, Ind ia T +91 ~0 6659 ~333, 3980 ~333, 23~2 0500 I 501 LAURUS Labs F +91 ~0 66 59 ~320 I 3980 ~320 Knowledge . Innovation . Excellence January 28, 2021 To To The Corporate Relat
Slide 2: Q3 & 9M FY21 Investor Presentation
LAURUS LABS LIMITED Q3 & 9M FY21 INVESTOR PRESENTATION January 28, 2021 BSE: 540222 NSE : LAURUSLABS
Slide 3: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 4: Financial Snapshot – Q3 FY21
Financial Snapshot – Q3 FY21 ₹ Cr Revenue (YoY Gr 76 %) EBITDA (YoY Gr 189%) MARGIN % 33% 34% 1,288 29% 1,139 974 23% 21% 839 730 433 378 285 193 150 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 30 0 21% 21% PAT (YoY Gr 274%) 21 % EPS ₹ (face value ₹ 2/- per share)
Slide 5: Business Snapshot
Business Snapshot - API -FDF Overview • Devel opment, manufacture a nd sale • Devel oping a nd ma nufacturing oral • Contra ct devel opment and ma nufacturi ng s ervices for of APIs a nd Adva nced Intermediates s ol id formulations for LMIC, North gl obal pharmaceutical companies and s everal late s
Slide 6: Segmental Revenue Breakup
Segmental Revenue Breakup ₹ Cr Generics API Generics FDF Synthesis 731 452 430 571 352 148 522 292 127 267 116 424 100 360 78 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3 FY20 FY20 FY21 FY21 FY21 FY20 FY20 FY21 FY21 FY21 FY20 FY20 FY21 FY21 FY21 Q3 FY 21 Contribution • Generic API division showcased
Slide 7: Generic API Division
Generic API Division ₹ Cr Anti Viral API Onco API Other API 568 86 135 379 64 106 59 99 99 336 92 51 273 47 214 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q3 FY 21 Contribution 13% • Anti Viral API revenue showed a growth o
Slide 8: Generic FDF Division
Generic FDF Division ₹ Cr 452 430 352 292 267 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Generic FDF revenue showcased a healthy growth of 47% YoY • RoW Markets – Launched TLE400 in the LMIC market • North America – Sales were driven by increased volumes in the US • Commenced marketing of in-licensed p
Slide 9: Synthesis (CDMO) Division
Synthesis (CDMO) Division ₹ Cr 148 127 116 100 78 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 • Revenue from Custom Synthesis division showed a strong growth of 63% (YoY) • Total Number of Active Projects in the CDMO division stood at 49 as on Q3 FY21 • Incorporated Wholly Owned Subsidiary to give incre
Slide 10: 15 Years Journey so far
15 Years Journey so far As on As on As on Capabilities * Mar-11 Mar-16 Dec-20 Funds Flow Analysis(₹ Cr) * FY 06-FY 11 FY 11-FY 16 FY 16-FY 21** (for each period of 5 Yrs) Description of the ARV API API Pharmaceutical Sources Company company Company Company Cash Profit (PAT +Dep) 7 633 2,128 Team Str
Slide 11: 5 year Division wise Revenue Contribution
5 year Division wise Revenue Contribution Generic 7% 2% 9% 10% FDF 3% 13% 8% 8% 8% 29% 6% 9% 36% 8% Custom Synthesis 10% 14% 10% Other API 11% 10% 82% 7% 6% 77% 74% 66% Onco API 39% 38% Anti Viral API FY 16 FY 17 FY 18 FY 19 FY 20 9M FY 21 10
Slide 12: 5 years Return Ratios
5 years Return Ratios Pre Tax Return on Capital Return on Equity(2) (%) Net Debt/EBIDTA (3) (x) Employed(1) (%) 43.7% 40.0% 2.8x 2.2x 1.9x 1.9x 16.5% 17.4% 13.7% 14.1% 15.3% 11.9% 8.2% 6.2% 0.7x FY17 FY 18 FY 19 FY 20 9M FY21 FY17 FY 18 FY 19 FY 20 9M FY21 FY17 FY 18 FY 19 FY 20 9M FY21 Note: Based
Slide 13: Laurus Bio – Richcore
Laurus Bio – Richcore Laurus Labs has completed the acquisition of majority stake (72.55%) in Richcore Lifesciences Pvt Ltd (Richcore) valued at ₹ 340 Cr and the cost of acquisition of 72.55% stake is ₹ 246.67 Cr. funded through internal accruals. Laurus has acquired the stake from the existing
Slide 14: Manufacturing Facilities at Parawada, Vizag
Manufacturing Facilities at Parawada, Vizag Unit-I • Located at Jawaharlal Nehru Pharma City, Visakhapatnam, India. • API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing. • Commenced operations in 2007. • 328 reactors with 1,226 Kilo Liters capacity
Slide 15: Manufacturing Facilities at Achutapuram, Vizag
Manufacturing Facilities at Achutapuram, Vizag • Located at APIIC, Achutapuram, Visakhapatnam, India. (SEZ) Unit-II • FDF and API manufacturing facility • Commenced operations in 2017. • FDF - capacity of 5 bn tablets/capsules per year. Capacity expansion initiated and will be operational by Q1 FY22
Slide 16: Quality Focus & Regulatory Audits
Quality Focus & Regulatory Audits Facility Key Agencies Recent Inspection Year Kilo Lab – R&D USFDA 2016 – EIR received USFDA, WHO – Geneva, ANVISA, 2019 - 20 – EIR Received, Unit 1 COFEPRIS – Mexico and JZAMP Slovenia and cGMP certification received USFDA, WHO – Geneva, BGV Hamburg, 2019 - 20 – EIR
Slide 17: Strong R&D Capabilities
Strong R&D Capabilities R&D Centre - Hyd 166 160 134 134 114 85 7.4% 7.1% 5.6% 5.7% 4.8% 3.9% FY16 FY17 FY18 FY 19 FY 20 9M FY21 R&D Spend ₹ Cr % of Revenue Current Filings Status Therapy US ANDA Europe Canada Patents Patents ARV 15 4 5 DMFs Filed Granted Anti- Diabetic 3 3 2 Cumulative CVS 3 - - Fi
Slide 18: Outlook for FY21 & Beyond
Outlook for FY21 & Beyond Healthy Revenue visibility on the Changing business mix to drive Capacity augmentation to result back of robust Order Book growth in better return ratios • Partnership with Global Fund offers higher • Generic FDF segment contributed ~36% • Among top 5 in India in terms of v
Slide 19: Key Milestones
Key Milestones • Incorporated Laurus Synthesis Pvt. Ltd & a cquired assets of an API Unit i n Vizag • Acqui red Aspen’s South Africa Subsidiary – La urus Generics SA(PTY) Limited • Ma i den EIR received for Unit 4 • La urus Synthesis Inc USA i s merged with La urus Generics Inc USA. • INR 10 billion
Slide 20: Board of Directors & Leadership Team
Board of Directors & Leadership Team Executive Directors Name Background Dr Satyanarayana Chava Whole-time Director, Founder and Chief Executive Officer Ravi Kumar V V Whole-time Director and CFO Dr Lakshmana Rao C V Whole-time Director and Head, Quality Non-Executive Directors Name Background
Slide 21: Ownership Structure
Ownership Structure Corporate Structure All are 100% Subsidiaries except Laurus Labs Limited Richcore* India Sriam Labs Pvt Ltd. Laurus Holdings Ltd. Laurus Synthesis Laurus Generics SA *Richcore Lifesciences Pvt. Ltd (PTY) Limited Pvt. Ltd. (Laurus Bio) India UK 72.55% Laurus Generics ^Laurus Gener
Slide 22: Results Conference Call
Results Conference Call Results conference call on Friday January 29, 2021 at 11:00 AM IST Details of the conference call are as follows: Timing 11:00 am IST on Friday, January 29, 2021 Conference dial-in Universal Dial-In +91 22 6280 1148 India Local access Number +91 7045671221 Available all over
Slide 23: Contact us
Contact us About Laurus Labs Ltd. Laurus Labs is a leading research driven Pharmaceutical manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology .We are thri
Slide 24: Thank You
Thank You